Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
01 oct. 2021 08h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors
18 août 2021 08h30 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress
05 août 2021 16h01 HE
|
Codiak BioSciences, Inc.
– Initial safety and PK/PD data from Phase 1/2 study of exoSTING™ now expected in the fourth quarter of 2021 – – Initial safety and efficacy data from Phase 1 trial of exoIL-12™ in CTCL...
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021
07 juil. 2021 08h30 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles
06 juil. 2021 16h30 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences Expands Executive Leadership
15 juin 2021 08h00 HE
|
Codiak BioSciences, Inc.
– Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer – – Konstantin Konstantinov, Ph.D. named Chief Technology Officer – CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Codiak...
Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
02 juin 2021 08h30 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors
20 mai 2021 16h05 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas
11 mai 2021 08h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak Appoints Jennifer Wheler, M.D., as Chief Medical Officer
10 mai 2021 08h00 HE
|
Codiak BioSciences, Inc.
– Former Principal Investigator at MD Anderson Cancer Center and immuno-oncology drug developer at Novartis joins Codiak leadership – – Benny Sorensen, M.D, Ph.D. named SVP, Strategic Projects – ...